Food and Drug Administration's proposed approach to regulation of hematopoietic stem/progenitor cell products for therapeutic use.
about
Regenerative Therapy of Type 1 Diabetes Mellitus: From Pancreatic Islet Transplantation to Mesenchymal Stem CellsEstablishing a stem cell culture laboratory for clinical trials.The efficacy and safety of platelet-rich plasma and adipose-derived stem cells: an updateThe potential of adipose stem cells in regenerative medicine.
P2860
Food and Drug Administration's proposed approach to regulation of hematopoietic stem/progenitor cell products for therapeutic use.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Food and Drug Administration's ...... products for therapeutic use.
@ast
Food and Drug Administration's ...... products for therapeutic use.
@en
type
label
Food and Drug Administration's ...... products for therapeutic use.
@ast
Food and Drug Administration's ...... products for therapeutic use.
@en
prefLabel
Food and Drug Administration's ...... products for therapeutic use.
@ast
Food and Drug Administration's ...... products for therapeutic use.
@en
P1476
Food and Drug Administration's ...... products for therapeutic use.
@en
P2093
P304
P356
10.1016/S0887-7963(00)80002-4
P577
2000-04-01T00:00:00Z